Future trends and challenges in pathogenomics. A foresight study

EMBO Reports

Volumn 6, Issue 7, 2005, Pages 600-605

  Pompe, Sven ^a   Simon, Judith ^a   Wiedemann, Peter M ^a   Tannert, Christof ^b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DNA;

ANTIBIOTIC RESISTANCE; BIOINFORMATICS; BIOLOGICAL WARFARE; CLINICAL RESEARCH; CROWDING; DEFORESTATION; DISEASE TRANSMISSION; DNA FINGERPRINTING; DRUG RESEARCH; ENVIRONMENTAL SANITATION; FLUORESCENCE MICROSCOPY; GENE IDENTIFICATION; GENE SEQUENCE; GENE TECHNOLOGY; GENETIC ANALYSIS; HEALTH CARE AVAILABILITY; HEALTH CARE SYSTEM; HEALTH EDUCATION; HISTOPATHOLOGY; HUMAN; INFECTION PREVENTION; LAND USE; LASER MICROSCOPY; MEDICAL RESEARCH; MICROBIAL GENETICS; MOLECULAR MECHANICS; NANOTECHNOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PERSONAL HYGIENE; POLLUTION; POVERTY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SEASONAL VARIATION; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIOECONOMICS; SPECIES IDENTIFICATION; WATER QUALITY; WATER SUPPLY;

BACTERIA; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; GENOMICS; HUMANS; VIRUSES;

EID: 23744484880     PISSN: 1469221X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.embor.7400472     Document Type: Review

References (59)

1. Altekruse SF, Cohen ML, Swerdlow DL (1997) Emerging foodborne diseases. Emerg Infect Dis 3: 285-293
2. Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94: 12106-12111
3. Bonn D (1997) New antifungals make mayhem for mycoses. Lancet 350: 870
4. Breiman RF (2001) Vaccines as tools for advancing more than public health: perspectives of a former director of the National Vaccine Program office. Clin Infect Dis 32: 283-288
5. Bröker M (2003) Impfstoff-Forschung und - Entwicklung aus der Sicht der pharmazeutischen Industrie. BIOforum 12: 768-771
6. Brogden KA, Guthmiller JM, Taylor CE (2005) Human polymicrobial infections. Lancet 365: 253-255
7. Burke JP (2003) Infection control - a problem for patient safety. N Engl J Med 348: 651-656
8. Cangelosi GA, Freitag NE, Buckley MR (2005) From Outside to Inside: Environmental Microorganisms as Human Pathogens. Washington, DC, USA: American Society for Microbiology
9. Cars O, Nordberg P (2004) Antibiotic resistance - the faceless threat. Background document to 'The global threat of antibiotic resistance', Dag Hammarskjöld Foundation. www.dhf.uu.se/antibiotics¶rticipant/new_pdf/Faceless_Threat.pdf
10. Casadevall A, Dadachova E, Pirofski L (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2: 695-703
11. Cassell GH, Mekalanos J (2001) Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA 285: 601-605
12. Chan NY, Ebi KL, Smith F, Wilson TF, Smith AE (1999) An integrated assessment framework for climate change and infectious diseases. Environ Health Perspect 107: 329-337
13. Cleaveland S, Laurenson MK, Taylor LH (2001) Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence. Philos Trans R Soc Lond B Biol Sci 356: 991-999
14. Cockerill FR 3rd, Smith TF (2004) Response of the clinical microbiology laboratory to emerging (new) and reemerging infection diseases. J Clin Microbiol 42: 2359-2365
15. Comley P (1997) The Use of the Internet for Opinion Polls. ESOMAR Congress 1997. www.virtualsurveys.com/news/papers/paper_8.asp
16. DeLong EF (2004) Microbial population genomics and ecology: the road ahead. Environ Microbiol 6: 875-878
17. Denning DW, Kibbler CC, Barnes RA (2003) British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 3: 230-240
18. Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167-193
19. Doyle TC, Burns SM, Contag CH (2004) In vivo bioluminescence imaging for integrated studies of infection. Cell Microbiol 6: 303-317
20. EFPIA (2003) Medicines for Mankind. Brussels, Belgium: European Federation of Pharmaceutical Industries and Associations. www.efpia.org/6_publ/Medicinesformankind/scientific.pdf
21. EFPIA (2004) Barriers to Innovation in the Development of New Medicines in Europe and Possible Solutions to Address these Barriers. Brussels, Belgium: www.efpia.org/4_pos/Barriersinnovation1104.pdf
22. Enserink M (2004) A global fire brigade responds to disease outbreaks. Science 303: 1605
23. Fauci AS, Touchett N, Folkers GK (2005) Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerg Infect Dis 11: 519-525
24. Goossens H, Ferech M, Vander Stichele R, Elesvies M, ESAC Project Group (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365: 579-587
25. Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, Mumford JA, Holmes EC (2004) Unifying the epidemiologicial and evolutionary dynamics of pathogens. Science 303: 327-332
26. Guernier V, Hochberg ME, Guegan JF (2004) Ecology drives the worldwide distribution of human diseases. PLoS Biol 2: e141
27. Guillemot D, Courvalin P; French Working Party to Promote Research to Control Bacterial Resistance (2001) Better control of antibiotic resistance. Cell Infect Dis 33: 542-547
28. Hacker J, Carniel E (2001) Ecological fitness, genomic islands and bacterial pathogenicity. A Darwinian view of the evolution of microbes. EMBO Rep 2: 376-381
29. Hampton T (2004) Modeling epidemics, bioterror. JAMA 291: 2933
30. Hatfull GF, Jacobs WR Jr (eds) (2000) Molecular Genetics of Mycobacteria. Washington, DC, USA: ASM Press
31. Kipp F, Friedrich AW, Becker K, von Eiff C (2004) Bedrohliche Zunahme Methicillin-resistenter S. aureus Stämme: Strategien zur Kontrolle und Prävention in Deutschland. Deutsch Ärztebl 101: 2045-2050
32. Lederberg J (2000) Infectious history. Science 288: 287-293
33. Levy SB (2001) Antibiotic resistance: consequences of inaction. Clin Infect Dis 33: S124-S129
34. Mabey D, Peeling RW, Ustianowski A, Perkins MD (2004) Diagnostics for the developing world. Nat Rev Microbiol 2: 231-240
35. Mangili A, Gendreau MA (2005) Transmission of infectious diseases during commercial air travel. Lancet 365: 989-996
36. May T, Silverman R (2003) Bioterrorism defense priorities. Science 301: 17
37. McNeil MM, Nash SL, Hajjeh, RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33: 641-647
38. Morens DM, Folkers GK, Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430: 242-249
39. Murray CJ, Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S (2003) Comparative quantification of health risks: conceptual framework and methodological issues. Popul Health Metr 1: 1-20
40. Nathan C (2004) Antibiotics at the crossroads. Nature 431: 899-902
41. NIAID (1999) Understanding emerging and re-emerging diseases. Bethesda, MD, USA: NIAID. www.niaid.nih.gov/publications/pdf/curriculum.pdf
42. Pang T, Guindon E (2004) Globalization and risks to health. EMBO Rep 5: S11-S16
43. Parsek MR, Fuqua C (2004) Biofilms 2003: emerging themes and challenges in studies of surface-associated microbial life. J Bacteriol 186: 4427-4440
44. Rappert B (2003) Biological weapons, genetics, and social analysis: emerging responses, emerging issues. II. New Genet Soc 22: 297-314
45. Rappuoli R (2004) From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med 10: 1177-1185
46. Ridley RG (2003) Product R&D for neglected diseases. EMBO Rep 4: S43-S46
47. Roux P, Münter S, Frischknecht F, Herbomel P, Shorte SL (2004) Focusing light on infection in four dimensions. Cell Microbiol 6: 333-343
48. Sheehan K (2001) E-mail Survey Response Rates: A Review. J Comp Mediated Comm 6. www.ascusc.org/jcmc/vol6/issue2/sheehan.html
49. Sheridan C (2005) Antiinfective biotechs face partnering gap. Nat Biotechnol 23: 155-156
50. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr (2004)Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38: 1279-1286
51. Sutherst RW (2004) Global change and human vulnerability to vector-borne diseases. Clin Microbiol Rev 17: 136-173
52. Totten JW (2002) Use of E-mail And Internet Survey By Research Companies. J Online Res. www.ijor.org/ijor_archives/articles /use_of_email_and_internet_Surveys.pdf
53. Weinstock GM (2000) Genomics and bacterial pathogenesis. Emerg Infect Dis 6: 496-504
54. WHO (2004) Public health response to biological and chemical weapons: WHO guidance. Geneva, Switzerland: World Health Organization. www.who.int/csr/delibepidemics/biochemguide/en/index.html
55. Williams RJ, Heymann DL (1998) Containment of antibiotic resistance. Science 279: 1153-1154
56. Wilson ME (1995) Travel and the emergence of infectious diseases. Emerg Infect Dis 1: 39-46
57. Woodall JP (2005) WHO and biological weapons investigations. Lancet 365: 651
58. Woolhouse ME (2002) Population biology of emerging and re-emerging pathogens. Trends Microbiol 10: S3-S7
59. Woolhouse ME, Taylor LH, Haydon DT (2001) Population biology of multihost pathogens. Science 292: 1109-1112